Lupin and Natco Gain FDA Approval for Eribulin Mesylate Injection, Entering Halaven Generic Market

Two Indian manufacturers now hold FDA approval for a generic oncology injectable that has, until now, faced limited competition in the US market. Lupin and Natco have each received clearance for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, bioequivalent to Eisai's reference listed drug Halaven, a microtubule inhibitor indicated for metastatic breast cancer and liposarcoma.

For QA directors and supply chain leads at sterile injectables sites, the approval signals a tightening competitive field for a low-volume, high-complexity oncology product. Eribulin mesylate manufacturing demands rigorous sterility assurance protocols and process validation aligned with 21 CFR Part 211 and ICH Q10 quality system expectations, the bar for entry is not trivial, which makes dual approvals from Indian manufacturers in a single cycle notable.

The supply-chain read is direct: two additional approved sources for a critical oncology injectable reduces single-supplier dependency risk for US hospital formularies and group purchasing organisations. Pricing pressure on the branded Halaven is a foreseeable downstream effect, consistent with the pattern seen across other generic oncology injectables where Indian manufacturers have entered with competitive ANDAs.

Lupin and Natco each bring established US generics infrastructure, but commercial launch timing, batch release capacity, and distribution agreements will determine how quickly either firm captures formulary position. Regulatory affairs leads tracking the oncology injectables pipeline should note that FDA's willingness to clear multiple applicants in proximity reflects the agency's competitive generics therapy (CGT) prioritisation for products with limited generic availability.

The measurable outcome to watch is market share movement against Halaven within the first two quarters post-launch, alongside any REMS or labelling parity requirements that could affect substitution at the dispensing level.

Source: Media4Growth via Indian Pharma Post, 2 June 2026.